Julia Shapiro
Overview
Explore the profile of Julia Shapiro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
81
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mendis S, Lipton L, To Y, Ananda S, Michael M, McLachlan S, et al.
Br J Cancer
. 2024 Mar;
130(9):1477-1484.
PMID: 38448752
Background: Pancreatic cancer incidence is increasing in younger populations. Differences between early onset pancreatic cancer (EOPC) and later onset pancreatic cancer (LOPC), and how these should inform management warrant exploration...
2.
Fernando M, Anton A, Weickhardt A, Azad A, Uccellini A, Brown S, et al.
J Geriatr Oncol
. 2023 Sep;
14(8):101621.
PMID: 37683368
Introduction: Prostate cancer (PC) is the second commonest malignancy and fifth leading cause of cancer death in men worldwide. Older men are more likely to develop PC but are underrepresented...
3.
Pereira-Salgado A, Anton A, Franchini F, Mahar R, Kwan E, Wong S, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2022 Dec;
23(2):231-239.
PMID: 36541133
Introduction: Health economic outcomes of real-world treatment sequencing of androgen receptor-targeted agents (ARTA) and docetaxel (DOC) remain unclear. Material And Methods: Data from the electronic Castration-resistant Prostate cancer Australian Database...
4.
Kelly R, Jensen A, Karunaratna N, Wong S, Shapiro J, Weickhardt A, et al.
BJU Int
. 2022 Nov;
131(2):179-182.
PMID: 36371671
No abstract available.
5.
Bakouny Z, El Zarif T, Dudani S, Wells J, Gan C, Donskov F, et al.
Eur Urol
. 2022 Oct;
83(2):145-151.
PMID: 36272943
Background: The role of upfront cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) in the era of immune checkpoint inhibitors is unclear. Objective: To evaluate the relationship between upfront...
6.
Santucci J, Tacey M, Thomson B, Michael M, Wong R, Shapiro J, et al.
Eur J Cancer
. 2022 Aug;
174:102-112.
PMID: 35988408
Background: First-line palliative chemotherapy regimens in advanced pancreatic ductal adenocarcinoma (PDAC) have not been compared in head-to-head phase III randomised controlled trials (RCT). Data on optimum first-line treatment and subsequent...
7.
Anton A, Pillai S, Semira M, Wong S, Shapiro J, Weickhardt A, et al.
BJUI Compass
. 2022 May;
3(3):205-213.
PMID: 35492221
Introduction: Several systemic therapies have demonstrated a survival advantage in metastatic castration resistant prostate cancer (mCRPC). Access to these medications varies significantly worldwide. In Australia until recently, patients must have...
8.
Chazan G, Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, et al.
Asia Pac J Clin Oncol
. 2022 Jan;
18(6):642-649.
PMID: 35098653
Aims: Multiple life-prolonging therapies are available for metastatic castration-resistant prostate cancer (mCRPC). However, the optimal treatment strategy following progression through standard treatment with docetaxel, androgen receptor signaling inhibitor (ARSI) and...
9.
To Y, Shapiro J, Wong R, Thomson B, Nagrial A, Mendis S, et al.
Asia Pac J Clin Oncol
. 2021 Nov;
18(4):448-455.
PMID: 34811944
Background: Prior studies have reported for several cancer types that treatment in the private sector is associated with improved survival outcomes. Data for patients with locally advanced unresectable and metastatic...
10.
Kelly R, Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, et al.
BJU Int
. 2021 Oct;
128 Suppl 1:18-26.
PMID: 34622543
Objectives: To investigate the recent real-world use of first-generation antiandrogens (FGAs) in metastatic castration-resistant prostate cancer (mCRPC) using a retrospective multicentre cohort study. Patients And Methods: The electronic CRPC Australian...